The first-generation, such as gefitinib and erlotinib usually with 4-anilinoquinazoline motifs, achieves initial good responses in the treatment of cancer patients with overexpression of EGFR but unfortunately, resistance to this class was acquired by most patients within 1 year.17 The gene discussed is EGFR; the disease is cancer.